Management of KSHV/HHV8-Positive Multicentric Castleman Disease Concurrent With Other KSHV/HHV8-Positive Disorders: An Emergent Challenge in PLWH
- 1 May 2025
- journal article
- letter
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (1) , e1-e2
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 11 references indexed in Scilit:
- Combined Flow‐Fluorescence in situ hybridization to HHV‐8 and EBV reveals the viral heterogeneity of primary effusion lymphomaJournal of Medical Virology, 2024
- Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and managementBlood Reviews, 2024
- Persistent CD38 Expression on CD8+ T Lymphocytes Contributes to Altered Mitochondrial Function and Chronic Inflammation in People With HIV, Despite ARTJAIDS Journal of Acquired Immune Deficiency Syndromes, 2022
- A novel approach for characterization of KSHV‐associated multicentric Castleman disease from effusionsBritish Journal of Haematology, 2022
- Castleman diseaseNature Reviews Disease Primers, 2021
- Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseasesBlood Advances, 2021
- Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman diseaseBlood, 2020
- Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016JAMA Network Open, 2020
- Clinical Features and Outcome in HIV-Associated Multicentric Castleman's DiseaseJournal of Clinical Oncology, 2011
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009